Antivirals market facing generics threat, especially for HIV drugs

Generic copies of branded drugs are predicted to take over the antiviral drugs market, especially in the case of HIV medication, as a series of patent expiries will open opportunities for ambitious companies to seize huge revenue, according to a new report by health care experts GBI Research.

The new report states that an increase in the patient population and reforms in government policies will work together to encourage the rise of generic pharmaceutical powers.

Government policies include the need for prior authorization in order to dispense branded drugs that have generic alternatives, while further incentives are available from Pharmacy Benefit Managers (PBM) for dispensing generic drugs. These kinds of regulatory changes and financial benefits could act as significant drivers of the market during the forecast period.